Cellular Mechanisms of Multiple Myeloma Bone Disease

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td align="left">Name of the drug</td><td align="center">Action</td><td align="center">Bone target cell/s</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td align="left">Denosumab</td><td align="center">RANKL neutralizing antibody</td><td align="center">OCs</td></tr><tr><td align="left">LY2127399</td><td align="center">BAFF neutralizing antibody</td><td align="center">OCs</td></tr><tr><td align="left">MLN3897</td><td align="center">CCR1 inhibitor</td><td align="center">OCs</td></tr><tr><td align="left">BHQ880</td><td align="center">DKK1 neutralizing antibody</td><td align="center">OBs</td></tr><tr><td align="left">ACE-011 (sotatercept)</td><td align="center">Activin A neutralizing receptor </td><td align="center">OCs and OBs</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Novel drugs for multiple myeloma bone disease.

Journal of Immunology Research

tab1

Table 1

Table 1: Cellular Mechanisms of Multiple Myeloma Bone Disease 